VCP and ovarian carcinoma: In the recently published paper in Cell Death and Discovery entitled, “Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors”, we employed a combination of incremental and continuous dosing scheme to establish CB-5083 resistant ovarian cancer cell lines.10 We identified two heterozygous mutations, E470D and E470K, in the D1–D2 linker region.